Inspira Technologies Oxy B.H.N. (NASDAQ:IINN – Get Free Report) was upgraded by equities researchers at Litchfield Hills Research to a “strong-buy” rating in a report issued on Monday, Marketbeat reports. The firm currently has a $2.00 target price on the stock. Litchfield Hills Research’s price objective indicates a potential upside of 221.03% from the stock’s current price.
Inspira Technologies Oxy B.H.N. Stock Performance
IINN opened at $0.62 on Monday. The firm has a 50-day moving average of $0.58 and a 200 day moving average of $0.86. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.13 and a current ratio of 2.23. Inspira Technologies Oxy B.H.N. has a fifty-two week low of $0.40 and a fifty-two week high of $2.31.
Hedge Funds Weigh In On Inspira Technologies Oxy B.H.N.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC boosted its position in Inspira Technologies Oxy B.H.N. by 422.5% during the fourth quarter. Citadel Advisors LLC now owns 86,763 shares of the company’s stock worth $88,000 after purchasing an additional 70,159 shares during the period. Virtu Financial LLC raised its stake in shares of Inspira Technologies Oxy B.H.N. by 254.4% during the first quarter. Virtu Financial LLC now owns 47,015 shares of the company’s stock worth $31,000 after acquiring an additional 33,749 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Inspira Technologies Oxy B.H.N. by 142.7% during the fourth quarter. Renaissance Technologies LLC now owns 36,622 shares of the company’s stock worth $37,000 after acquiring an additional 21,532 shares in the last quarter. Institutional investors own 12.72% of the company’s stock.
About Inspira Technologies Oxy B.H.N.
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.
See Also
- Five stocks we like better than Inspira Technologies Oxy B.H.N.
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Why Super Micro Computer’s Upside Could Trigger a Short Squeeze
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Companies to Buy on This Early Cycle Recovery
- How to Plot Fibonacci Price Inflection Levels
- Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade
Receive News & Ratings for Inspira Technologies Oxy B.H.N. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspira Technologies Oxy B.H.N. and related companies with MarketBeat.com's FREE daily email newsletter.
